Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated Tumors

Cristiana Sessa, MD
Published: Wednesday, Nov 08, 2017



Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

The role of ATR inhibitors is to protect the genomic integrity of cells by blocking the cell cycle and allowing them time to repair, says Sessa.

ATR inhibitors can be used in combination with other drugs such as PARP inhibitors. Also, they can be used in tumor types with a lack of p53 or tumors with ataxia–telangiectasia mutation (ATM)-deficient.
 


Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

The role of ATR inhibitors is to protect the genomic integrity of cells by blocking the cell cycle and allowing them time to repair, says Sessa.

ATR inhibitors can be used in combination with other drugs such as PARP inhibitors. Also, they can be used in tumor types with a lack of p53 or tumors with ataxia–telangiectasia mutation (ATM)-deficient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x